Dilated cardiomyopathy is characterized by left ventricular dilation with systolic dysfunction (EF <50%) in the absence of coronary artery disease or abnormal loading conditions. It affects approximately 1 in 2,500 people, typically presents in the 4th–6th decade, and is the most common indication for heart transplantation globally. [1-3]
1. History
- Dyspnea on exertion, orthopnea, paroxysmal nocturnal dyspnea (PND), fatigue — classic HF symptoms present in ~80% at diagnosis [4]
- Ankle/peripheral edema, weight gain, abdominal distension
- Palpitations, presyncope, syncope (arrhythmia-related)
- Timing: insidious onset over weeks to months vs. acute decompensation
- Triggers: recent viral illness, pregnancy (peripartum), new chemotherapy, alcohol/drug use
- Exercise intolerance — quantify functional class (NYHA I–IV)
- Ask about prior cardiac history, chest pain, and thromboembolic events (stroke, DVT/PE)
- Important negatives: absence of angina, valvular disease symptoms, hypertensive history [5-6]
2. Alarm Features
- Cardiogenic shock: hypotension, altered mental status, cool extremities, oliguria
- Syncope or near-syncope (suggests ventricular arrhythmia or severe low output)
- New-onset sustained ventricular tachycardia or ventricular fibrillation
- Acute pulmonary edema with respiratory failure
- Thromboembolic events (stroke, peripheral embolism) — can be the initial presentation [4]
- Sudden cardiac death — particularly in LMNA, RBM20, FLNC, DSP gene carriers [5]
- Rapid clinical deterioration despite initial therapy
3. Medications
Medications that can CAUSE DCM: [5][7]
- Anthracyclines (doxorubicin) — dose-dependent, may present >10 years after exposure
- Trastuzumab, cyclophosphamide, 5-FU
- Cocaine, amphetamines, alcohol (≥80 g/day for >5 years)
- Clozapine, chloroquine, hydroxychloroquine
Guideline-directed medical therapy (GDMT) — "Quadruple Therapy": [5][8]
- ACE inhibitor/ARB (or sacubitril-valsartan if symptomatic despite ACEi/ARB)
- Beta-blocker (carvedilol, bisoprolol, or metoprolol succinate)
- Mineralocorticoid receptor antagonist (spironolactone or eplerenone)
- SGLT2 inhibitor (dapagliflozin or empagliflozin)
Additional agents:
- Loop diuretics for congestion (symptom control; no mortality benefit)
- Ivabradine if HR >70 bpm in sinus rhythm despite beta-blocker
- Hydralazine/isosorbide dinitrate — recommended for persistently symptomatic Black patients
- Digoxin for refractory symptoms or rate control in atrial fibrillation
- Anticoagulation for atrial fibrillation (especially high-risk in LMNA carriers) [5]
Contraindicated medications: [8]
- Nondihydropyridine calcium channel blockers (verapamil, diltiazem) if EF ≤50%
- Thiazolidinediones
- NSAIDs (fluid retention, renal effects)
The following figure illustrates the stepwise approach to initiating and optimizing GDMT in heart failure:
4. Diet
- Sodium restriction: <2 g/day for symptomatic HF
- Fluid restriction: 1.5–2 L/day in patients with refractory congestion or hyponatremia
- Alcohol cessation — mandatory if alcoholic cardiomyopathy is suspected; even moderate reduction may improve EF
- Nutritional assessment: thiamine, selenium, carnitine deficiency can cause or worsen DCM [7]
- Daily weight monitoring to detect fluid retention early
- Heart-healthy diet (Mediterranean-style) for long-term cardiovascular risk reduction
5. Review of Systems
- Cardiovascular: chest pain, palpitations, syncope, edema, exercise intolerance
- Pulmonary: dyspnea, orthopnea, PND, cough (especially nocturnal)
- GI: early satiety, nausea, RUQ pain (hepatic congestion), anorexia, cachexia [4]
- Neurologic: dizziness, lightheadedness, TIA/stroke symptoms
- Musculoskeletal: muscle weakness (consider muscular dystrophy-associated DCM — elevated CK) [5]
- Endocrine: symptoms of thyroid disease, Cushing syndrome, pheochromocytoma
- Constitutional: fatigue, weight changes, fevers (myocarditis)
6. Collateral History and Family History
- Three-generation pedigree is essential — DCM is familial in 20–35% of cases; inherited DCM exists in ~50% of pediatric cases [2][4][6]
- Ask about unexplained sudden cardiac death in relatives <50 years old
- Family members with heart failure, pacemakers, ICDs, heart transplantation, arrhythmias, or neuromuscular disease [5]
- DCM is considered familial if ≥2 first- or second-degree relatives are affected, or a first-degree relative had autopsy-proven DCM and sudden death <50 years [5]
- Autosomal dominant inheritance is most common; X-linked (dystrophin, Emery-Dreifuss) also important [10]
- Social history: alcohol quantification, recreational drug use, occupational toxin exposure, chemotherapy history, recent pregnancy
7. Risk Factors
- Genetic: TTN truncating variants (most common genetic cause), LMNA, MYH7, DSP, FLNC, RBM20 [5][11]
- Toxic: chronic alcohol use, cocaine, amphetamines, anthracycline chemotherapy [7]
- Infectious: viral myocarditis (Coxsackie B, adenovirus, parvovirus B19, HIV), Chagas disease [7]
- Autoimmune/inflammatory: sarcoidosis, SLE, scleroderma, giant cell myocarditis [7]
- Endocrine: hypothyroidism, hyperthyroidism, pheochromocytoma, acromegaly
- Peripartum: onset in last month of pregnancy to 5 months postpartum [4]
- Tachycardia-induced: persistent tachyarrhythmia >100 bpm [7]
- Nutritional: thiamine (beriberi), selenium, carnitine deficiency
- Sex: disease appears more penetrant in men for most genetic subtypes (except DSP) [11]
8. Differential Diagnosis
- Ischemic cardiomyopathy — most important to exclude; coronary angiography or stress testing needed
- Hypertensive heart disease — chronic pressure overload leading to LV dilation
- Valvular heart disease — aortic stenosis/regurgitation, mitral regurgitation
- Myocarditis (acute) — may mimic or evolve into DCM; troponin elevation, recent viral illness
- Tachycardia-induced cardiomyopathy — reversible with rate/rhythm control within ~4 weeks [7]
- Arrhythmogenic cardiomyopathy (left-dominant ARVC) — can phenotypically overlap with DCM [1][12]
- Burned-out hypertrophic cardiomyopathy — end-stage HCM with LV dilation
- Left ventricular noncompaction [12]
- Cardiac sarcoidosis — AV block, LGE on CMR, hilar lymphadenopathy
- Stress (Takotsubo) cardiomyopathy — acute, typically with apical ballooning
- Peripartum cardiomyopathy — temporal relationship to pregnancy [4]
9. Past Medical History
- Prior heart failure episodes, known cardiomyopathy, or cardiac procedures
- Cancer history and chemotherapy exposure (anthracyclines, trastuzumab — cumulative dose matters) [7]
- Autoimmune diseases (SLE, sarcoidosis, scleroderma)
- Neuromuscular disorders (Duchenne/Becker muscular dystrophy, myotonic dystrophy)
- Endocrine disorders (thyroid disease, diabetes)
- HIV status
- Substance use history (alcohol, cocaine, amphetamines)
- Prior myocarditis or viral illness
- Pregnancy history (peripartum cardiomyopathy)
10. Physical Exam
Vital signs
Key findings: [4]
- JVD (elevated jugular venous pressure)
- Displaced PMI — inferolaterally displaced, diffuse apex beat
- S3 gallop — volume overload; persistent S3 implies poor prognosis [13]
- Mitral regurgitation murmur — holosystolic at apex (functional MR from annular dilation)
- Pulmonary crackles/rales — pulmonary congestion
- Peripheral/sacral edema
- Hepatomegaly, hepatojugular reflux, ascites (right-sided failure)
- Cool extremities, delayed capillary refill (low cardiac output)
- Cachexia in advanced disease
11. Lab Studies
Routine labs: [5][7]
- BNP/NT-proBNP — diagnosis, severity, and prognostication; most widely adopted biomarker
- Troponin (high-sensitivity) — myocardial injury; elevated in myocarditis, ongoing myocardial stress
- CBC with differential (anemia, eosinophilia)
- BMP (renal function, electrolytes — hyponatremia is a poor prognostic sign)
- LFTs, GGT (hepatic congestion, alcohol use)
- TSH (hypo/hyperthyroidism)
- Iron studies (ferritin, transferrin saturation — hemochromatosis)
- CRP/ESR (inflammatory/autoimmune causes)
- HIV serology (in patients with risk factors or unexplained DCM)
- CK (elevated in muscular dystrophies, mitochondrial disease) [5]
- Urine toxicology if cocaine/amphetamine use suspected
Selective labs
- Trypanosoma cruzi serology (travel to Central/South America)
- Lyme serology if suspected
- ACE level (sarcoidosis)
- Urinary metanephrines (pheochromocytoma)
- Genetic testing — recommended in all patients with DCM regardless of family history [5]
12. Imaging
First-line: Transthoracic echocardiography [4-5]
- LV dilation with global hypokinesis (regional wall motion abnormalities possible)
- Reduced LVEF (<50%; often <35% at presentation)
- Functional mitral regurgitation, LA dilation
- Assess RV function, diastolic parameters, intracardiac thrombus
Gold standard for tissue characterization: Cardiac MRI (CMR) [3][5]
- Accurate biventricular volumes and EF
- Late gadolinium enhancement (LGE) — fibrosis/scar; present in many DCM patients and strongly prognostic
- T2 mapping — myocardial edema (myocarditis, sarcoidosis)
- T1 mapping — diffuse fibrosis
- Should be performed early in the diagnostic workup
Chest X-ray: cardiomegaly, pulmonary venous congestion, pleural effusions [4]
Coronary angiography or CT coronary angiography: to exclude ischemic etiology — essential in the workup [6]
When imaging is unnecessary: repeat echocardiography is not needed at every visit unless clinical change or to reassess after GDMT optimization
13. Special Tests
- Endomyocardial biopsy (EMB): considered when myocarditis, sarcoidosis, giant cell myocarditis, or eosinophilic myocarditis is suspected; limited by sampling error [4][14]
- Genetic testing and counseling: recommended for all DCM patients; >50 genes implicated; TTN truncating variants are the most common cause (~15–25% of familial DCM) [5]
- Holter/ambulatory ECG monitoring: assess arrhythmia burden, especially in LMNA, TTN, RBM20, FLNC, DSP carriers [5]
- Cardiopulmonary exercise testing (CPET): peak VO₂ and VE/VCO₂ slope for prognosis and transplant evaluation [15]
- 18F-FDG PET: emerging tool for cardiac sarcoidosis diagnosis and monitoring [7]
- Cascade screening of first-degree relatives: echocardiography every 3–5 years; more frequently if abnormalities detected [2]
14. ECG
Common findings: [4-5][10]
- Sinus tachycardia
- Nonspecific ST-T wave changes
- Low-voltage QRS
- Poor R-wave progression
- Left atrial enlargement
- Left ventricular hypertrophy pattern
- Left bundle branch block (LBBB) — important for CRT candidacy
Gene-specific patterns: [5]
- LMNA: sinus bradycardia, AV block (first-degree → complete), atrial fibrillation — may precede DCM
- DSP/FLNC/PLN: lateral T-wave inversions, low QRS voltage, frequent PVCs
- Ventricular ectopy, nonsustained or sustained VT
Dangerous patterns to recognize
- High-grade AV block (LMNA, sarcoidosis, giant cell myocarditis)
- Sustained ventricular tachycardia
- New atrial fibrillation with rapid ventricular response
- Epsilon waves (consider arrhythmogenic cardiomyopathy overlap)
15. Assessment
DCM is defined by LV enlargement + EF <50% after excluding ischemic, valvular, and hypertensive etiologies. [1] The etiology is heterogeneous — genetic (~30–40%), post-infectious, toxic, autoimmune, or idiopathic. [5][16] Severity is stratified by NYHA class, LVEF (≤35% is a critical threshold for device therapy), BNP levels, and CMR findings (LGE burden). [5][13]
Typical presentation: gradual-onset HF symptoms in a middle-aged adult with dilated LV on echo.
Atypical presentations: arrhythmia or conduction disease as the initial manifestation (especially LMNA); thromboembolic event; incidental finding on imaging; peripartum onset. [4-5]
Complications: progressive HF, atrial fibrillation, ventricular arrhythmias/SCD, thromboembolism, cardiogenic shock, end-organ dysfunction. [16]
Approximately 25% of patients with recent-onset symptoms may have spontaneous improvement, but those with symptoms >3 months and severe decompensation have less chance of recovery. [13]
16. Treatment Plan
Acute decompensation (ED/inpatient): [4]
- IV furosemide for decongestion (dose and route based on severity)
- Sublingual or IV nitroglycerin for pulmonary congestion
- Vasopressors/inotropes (dobutamine, milrinone, norepinephrine) for cardiogenic shock
- Non-invasive ventilation (BiPAP) for acute pulmonary edema
- Identify and treat precipitants (arrhythmia, infection, medication nonadherence, dietary indiscretion)
Chronic management — initiate GDMT as early as possible: [5][8]
- All four pillars (ACEi/ARB/ARNI + beta-blocker + MRA + SGLT2i) should be started within 4–6 weeks of diagnosis, titrated to target doses
- Do NOT withdraw GDMT even if EF normalizes — TRED-HF showed 44% relapse within 6 months [5]
Device therapy: [5][14]
- ICD: consider for primary prevention if LVEF ≤35% despite ≥3 months of optimal GDMT (though DANISH trial tempered enthusiasm in non-ischemic DCM, especially in older patients)
- CRT (±ICD): LVEF ≤35% + LBBB + QRS ≥150 ms + NYHA II–IV
- Genetic-specific risk: LMNA, RBM20, FLNC, DSP carriers may warrant ICD at higher EF thresholds
Advanced therapies: LVAD, heart transplantation for refractory Stage D HF [14][16]
Etiology-specific treatment
- Alcohol cessation for alcoholic cardiomyopathy
- Immunosuppression for giant cell myocarditis, cardiac sarcoidosis
- Rate/rhythm control for tachycardia-induced cardiomyopathy (expect recovery within ~4 weeks) [7]
- Anticoagulation for AF (especially LMNA-related DCM) [5]
17. Disposition
Admit if: [4][13]
- New-onset HF with hemodynamic instability
- Acute decompensated HF requiring IV diuretics or vasoactive agents
- Cardiogenic shock
- Symptomatic arrhythmias (sustained VT, high-grade AV block, new rapid AF)
- Syncope in the setting of known or suspected DCM
- Significant end-organ dysfunction (renal failure, hepatic congestion)
- Need for urgent advanced workup (EMB, cardiac catheterization)
Observation
- Mild decompensation responding to IV diuresis with stable vitals
- New diagnosis with mild symptoms, pending workup
Discharge criteria
- Hemodynamically stable, euvolemic or near-euvolemic
- Transitioned to oral diuretics with stable weight
- GDMT initiated or optimized
- Outpatient follow-up arranged (cardiology within 1–2 weeks)
- Patient education completed (daily weights, sodium restriction, medication adherence)
Specialist consultation triggers
- All new DCM diagnoses → cardiology referral
- LVEF ≤35% → electrophysiology for device evaluation
- Suspected genetic etiology → genetic counseling
- Refractory HF → advanced HF/transplant team (use I-NEED-HELP mnemonic: IV inotropes, NYHA III–IV, End-organ dysfunction, EF ≤35%, Defibrillator shocks, Hospitalizations, Edema despite diuretics, Low BP, Prognostic medication intolerance)
18. Follow Up / Return Precautions
Follow-up timing: [2][17]
- Post-discharge: cardiology within 7–14 days
- GDMT titration visits every 1–4 weeks until target doses achieved
- Repeat echocardiography at 3–6 months after GDMT optimization to reassess EF
- CMR if not yet obtained
- Genetic testing and family screening if not yet initiated
- First-degree relatives: screening every 3–5 years (more frequently if abnormalities detected) [2]
Return precautions — instruct patients to seek immediate care for:
- Worsening dyspnea at rest or with minimal exertion
- Weight gain >2–3 lbs in 24 hours or >5 lbs in a week
- New or worsening edema
- Syncope or presyncope
- Palpitations or irregular heartbeat
- Chest pain
- Inability to lie flat
Patient counseling
- Daily weight monitoring at the same time each morning
- Strict sodium restriction (<2 g/day)
- Medication adherence is critical — do not stop medications even if feeling better
- Alcohol avoidance
- Moderate exercise as tolerated (cardiac rehab when stable)
- Avoid NSAIDs
- Pregnancy counseling for women of childbearing age (high-risk; contraception discussion essential)
- Expected course: some patients improve significantly with GDMT; others progress — prognosis is highly variable depending on etiology, EF, and response to therapy [13]
References
1. Dilated Cardiomyopathy Overview. — Hershberger RE, Jordan E GeneReviews® [Internet]. 2024.
2. Cardiomyopathy: A Guide for Primary Care. — Coppiano J, Carrasco M, Asif I. American Family Physician. 2026.
3. Risk Stratification in Nonischemic Dilated Cardiomyopathy Using CMR Imaging: A Systematic Review and Meta-Analysis. — Eichhorn C, Koeckerling D, Reddy RK, et al. The Journal of the American Medical Association. 2024.
4. Dilated Cardiomyopathy. — Weintraub RG, Semsarian C, Macdonald P. Lancet. 2017.
5. Dilated Cardiomyopathy: Causes, Mechanisms, and Current and Future Treatment Approaches. — Heymans S, Lakdawala NK, Tschöpe C, Klingel K. Lancet. 2023.
6. Contemporary and Future Approaches To Precision Medicine in Inherited Cardiomyopathies: JACC Focus Seminar 3/5. — Fatkin D, Calkins H, Elliott P, et al. Journal of the American College of Cardiology. 2021.
7. The Diagnosis and Evaluation of Dilated Cardiomyopathy. — Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. Journal of the American College of Cardiology. 2016.
8. Management of Heart Failure: Updated Guidelines From the AHA/ACC. — Ford B, Dore M, Bartlett B. American Family Physician. 2023.
9. How to Initiate and Uptitrate GDMT in Heart Failure: Practical Stepwise Approach to Optimization of GDMT. — Bozkurt B. JACC. Heart Failure. 2022.
10. Sudden Death in the Young: Information for the Primary Care Provider. — Erickson CC, Salerno JC, Berger S, et al. Pediatrics. 2021.
11. Sex Differences in Dilated Cardiomyopathy: Evidence Gaps and Future Directions. — Stroeks SLVM, Oko-Osi S, Arasu A, Hirst JE, Tayal UP. Journal of the American College of Cardiology. 2026.
12. Utilities and Limitations of Cardiac Magnetic Resonance Imaging in Dilated Cardiomyopathy. — Cha MJ, Hong YJ, Park CH, et al. Korean Journal of Radiology. 2023.
13. Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart Association. — Bozkurt B, Colvin M, Cook J, et al. Circulation. 2016.
14. Dilated Cardiomyopathy. — Schultheiss HP, Fairweather D, Caforio ALP, et al. Nature Reviews. Disease Primers. 2019.
15. Emerging Techniques for Risk Stratification in Nonischemic Dilated Cardiomyopathy: JACC Review Topic of the Week. — Marrow BA, Cook SA, Prasad SK, McCann GP. Journal of the American College of Cardiology. 2020.
16. Dilated Cardiomyopathy: From Epidemiologic to Genetic Phenotypes: A Translational Review of Current Literature. — Reichart D, Magnussen C, Zeller T, Blankenberg S. Journal of Internal Medicine. 2019.
17. Treatment Strategies for Cardiomyopathy in Children: A Scientific Statement From the American Heart Association. — Bogle C, Colan SD, Miyamoto SD, et al. Circulation. 2023.